The SEC has opened an administrative proceeding against Novagant Corp., also identified as Golden Bee Health Products Investment Limited, Inc., over repeated failures to maintain current periodic reporting. The Nevada-incorporated issuer is listed by the SEC as being located in Hong Kong and continues to have unsolicited quotations submitted on OTC Link ATS under the symbol NVGT. According to the Commission, however, the company has filed no periodic report since a Form 10-Q covering the period ended December 31, 2023. The case creates a notable disconnect between continued market visibility and the age of the issuer's regulatory disclosures, particularly for investors who may encounter NVGT through OTC quotation services without first reviewing its SEC filing history.
U.S. Securities and Exchange Commission (SEC)
Official Release: https://www.sec.gov/files/litigation/admin/2026/34-106467.pdf
NEWS:
The SEC's September 22, 2026 order identifies Novagant Corp., also known as Golden Bee Health Products Investment Limited, Inc., as a Nevada corporation located in Hong Kong, China. The company has SEC CIK No. 1089297 and a class of securities registered under Exchange Act Section 12(g). The Commission alleges that Novagant is delinquent in its required periodic filings and has not submitted any periodic report since filing a Form 10-Q for the period ended December 31, 2023. At the same time, unsolicited quotations for its common stock continue to be submitted on OTC Link ATS under ticker NVGT.
The SEC also states that Novagant repeatedly failed to meet its timely filing obligations and either failed to respond to a delinquency letter from the Division of Corporation Finance or failed to receive the letter because it had not maintained a valid address with the Commission. That point is important because maintaining accurate issuer contact information is part of the broader disclosure infrastructure supporting public-market oversight. When both financial reporting and issuer contact records become stale, regulators and investors face greater difficulty determining the current operating status, management situation and financial condition of a quoted company.
The proceeding was brought under Section 12(j) of the Securities Exchange Act of 1934. That provision allows the Commission, after the administrative process, to suspend or revoke the registration of a class of securities when an issuer has failed to comply with Exchange Act requirements. The September order begins that process; it does not itself establish that Novagant's registration has already been revoked. The matter remains listed by the SEC as an open litigated administrative proceeding under File No. 3-22751.
WHY THIS CASE MATTERS:
Novagant presents a useful due-diligence problem because several identifiers can give an issuer an appearance of continued market presence even when its regulatory information is no longer current. The company still has a CIK, a registered class of securities and an OTC symbol, yet the SEC says its periodic reporting stopped with a filing covering 2023. Those facts should not be treated as equivalent indicators of regulatory standing. An SEC identifier confirms that a filing record exists; it does not by itself establish that the record is current.
The alternative corporate name also makes historical research more important. Investors searching only for "Novagant" or only for "Golden Bee Health Products Investment Limited" may encounter different fragments of the same issuer's history. Matching CIK 1089297, ticker NVGT and the SEC proceeding provides a more reliable way to connect those records. For thinly traded OTC issuers, identity continuity and filing chronology can be just as important as price history when determining whether publicly available information remains usable for investment analysis.
KEY POINTS:
- The SEC identifies the respondent as Novagant Corp., also known as Golden Bee Health Products Investment Limited, Inc.
- The issuer has SEC CIK No. 1089297.
- Its common stock is quoted under ticker NVGT through unsolicited OTC Link ATS quotations.
- The SEC says no periodic report has been filed since a Form 10-Q covering December 31, 2023.
- The Commission alleges repeated failures to comply with periodic reporting requirements.
- The proceeding was instituted under Exchange Act Section 12(j).
- The matter remains an open administrative proceeding and is not yet a final revocation order.
- Investors should connect the issuer's alternate names, CIK and ticker when reviewing its regulatory history.